---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-001724"
form_type: "8-K"
ticker: "LFWD"
cik: "0001607962"
company_name: "Lifeward Ltd."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:01:15.677432+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lifeward completes acquisition of Oratech Pharma, issues shares and convertible notes

## Summary
- Lifeward completed acquisition of Oratech Pharma on March 25, 2026, issuing 2,256,476 ordinary shares and pre-funded warrants to Oramed.
- Issued $10,000,000 aggregate principal amount of senior secured convertible notes and warrants in a private placement.
- Directors Dr. John William Poduska and Randel Richner resigned effective March 25, 2026.
- Appointed Nadav Kidron, Miriam Kidron, and Yehuda Reznick as new directors, expanding board from five to eight.
- Entered into a First Amendment and Assignment to assign Oratech Pharma rights to Oratech Ltd.

## SEC filing metadata
- accession: 0001178913-26-001724
- form_type: 8-K
- ticker: LFWD
- cik: 0001607962
- company_name: Lifeward Ltd.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/zk2634956.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-001724
- JSON: https://secwatch.observer/filing/0001178913-26-001724.json
- Plain text: https://secwatch.observer/filing/0001178913-26-001724.txt

## Key facts
- Equity Issuances
  Lifeward Ltd. issued convertible note to Oramed and certain investors for $10,000,000.00 aggregate principal amount.
  - Security: convertible note
  - Purchaser: Oramed and certain investors
  - Consideration: $10,000,000.00 aggregate principal amount
  source text: On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm
- Equity Issuances
  Lifeward Ltd. issued warrant to Oramed and certain investors.
  - Security: warrant
  - Purchaser: Oramed and certain investors
  source text: On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm
- M&A Transactions
  Lifeward Ltd. completed an acquisition involving Oramed Pharmaceuticals, Inc. (closed 2026-03-25).
  - Action: acquisition
  - Counterparty: Oramed Pharmaceuticals, Inc.
  - Closing: 2026-03-25
  source text: On March 25, 2026, the Company completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.